{"id":"NCT00656799","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Dialysis of Sugammadex in Participants With Severe Renal Impairment (Study 19.4.333) (P05773)","officialTitle":"A Single Center, Open-Label Trial in Subjects With Severe Renal Impairment Evaluating the Dialysability of the Sugammadex-Rocuronium Complex","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-04","primaryCompletion":"2009-07","completion":"2009-07","firstPosted":"2008-04-11","resultsPosted":"2013-07-31","lastUpdate":"2015-03-10"},"enrollment":6,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Neuromuscular Blockade"],"interventions":[{"type":"DRUG","name":"sugammadex","otherNames":["Org 25969","SCH 900616","MK-8616","Bridion®"]},{"type":"DRUG","name":"Rocuronium","otherNames":["Rocuronium bromide","Esmeron®"]}],"arms":[{"label":"Sugammadex","type":"EXPERIMENTAL"}],"summary":"The clinical trial objectives were to evaluate the dialysability of the sugammadex-rocuronium complex; it's safety and efficacy in participants with severe renal impairment.","primaryOutcome":{"measure":"Clearance of Sugammadex by Dialysis as Measured by the Reduction Ratio (RR)","timeFrame":"Up to day 7","effectByArm":[{"arm":"Sugammadex","deltaMin":0.687,"sd":0.113}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":7},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["22732111"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":6},"commonTop":["Hypoglycaemia","Thrombocytopenia","Arrhythmia","Cardiac failure","Constipation"]}}